Renaissance Capital logo

Shuttle Pharmaceuticals Priced, Nasdaq: SHPH

Phase 2-ready biotech developing drugs to improve radiation therapy.

Industry: Health Care

Latest Trade: $1.50 -0.10 (-6.3%)

First Day Return: +373.3%

Return from IPO: -80.3%

Industry: Health Care

Founded in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharmaceuticals is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT). Our mission is to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of RT while limiting the late effects of radiation in cancer treatment. Although RT is a proven modality for treating cancers, by developing radiation sensitizers, we aim to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment, or in combination with surgery, chemotherapy and immunotherapy. We currently have no FDA approved products and we have not yet applied for a new drug application. To date, we have been funded by investments from private investors and government contracts obtained from the National Institutes of Health (NIH) for performing research.
more less
IPO Data
IPO File Date 06/03/2022
Offer Price $8.13
Price Range $8.13 - $8.13
Offer Shares (mm) 1.2
Deal Size ($mm) $10
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 08/30/2022
Offer Price $8.13
Price Range $8.13 - $8.13
Offer Shares (mm) 1.2
Deal Size ($mm) $10
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
Boustead Securities
Valuable Capital
Company Data
Headquarters Rockville, MD, United States
Founded 2012
Employees at IPO 5
Website www.shuttlepharma.com

Shuttle Pharmaceuticals (SHPH) Performance